AKTX · Akari Therapeutics Plc ADR
United States · RS rating 19 · As of 2026-10-14
| Price | 7.28 USD |
|---|---|
| 1-day change | -7.8% |
| RS rating (overall / 1M / 3M / 12M) | 19 / 7 / 9 / 6 |
| Stage | Declining |
| Composite / Minervini / CANSLIM score | 19 / 13 / 18 |
| Industry group (rank) | Medical-Biomed/Biotech (167) |
| EPS growth Q/Q | – |
| Sales growth Q/Q | – |
| Distance from 52-week high | +81.4% |
| Market cap (USD) | $6.9M |